The three-year targets are aspirational and not guidance; monitor for concrete sales data in future filings.
Price Chart
Executive Summary
Cosmos Health announced strong sales momentum for its proprietary antiseptic brands C-Scrub and C-Sept, with over $1.5 million in combined annualized sales and gross margins above 70%. The company outlined a three-year growth target to reach $7.4 million in revenue by 2028, but this press release is a business update, not an earnings release—no financial results for Q1 2026 were provided. The filing lacks current-period revenue, EPS, or guidance figures, making it a forward-looking narrative with no hard data to validate.
Key Facts
- C-Scrub and C-Sept have generated over $1.5 million in combined annualized sales across the UK and Greece.
- Gross margins on these brands exceed 70%.
- Three-year revenue target: ~$2.5M (2026), ~$4.2M (2027), ~$7.4M (2028), with corresponding gross profit targets.
- Expansion into additional EU markets and animal healthcare is planned.
- No current-period financial results (Q1 2026) were reported in this press release.
Financial Impact
The press release outlines aspirational revenue targets of $2.5M-$7.4M over three years, but no current financial data is provided. The $1.5M annualized sales figure is modest relative to the company's market cap of $13M.
Risk Factors
- No current financial results were provided; the press release is purely narrative.
- Three-year targets are aspirational and may not be achieved; no assurance of reaching stated revenue or margin goals.
- The company has a history of negative EPS and small market cap ($13M), increasing execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2610 (+3.16%) |
Oct 16, 2026 10d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2610 (−19.69%) |
Oct 9, 2026 17d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2610 (−25.34%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2610 (+1.88%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2610 (−35.23%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2610 (+13.33%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2610 (+11.16%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2610 (−7.02%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2610 (−6.28%) |
Jul 14, 2026 14w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2610 (−15.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers